Member Info for RichKen

I say that meaning sub £1.20!
If we get any news tomorrow or an RNS on news from Cytiva. Monday morning buying will be crazy. The MM’s will tick the SP up.
So to avoid missing the boat. Right now is your time.
Nobody knows when this news will come, but it is soon.
Cheers RK

You can be sure every ambulance will be carrying the Cytiva/Avacta test on board when they become available. Accurate and fast. With no issues of storage, temperature or size. Critical of all emergency services work.
Cheers RK

Following the excellent presentation last evening I have added a further £20k’s worth of shares all around 108. Very happy with this mornings work.
Within days the share price will be under pressure and this will result in a strong rise. We know there will be additional partnerships announced for either lateral flow devices or other delivery mechanisms for the Affirmers for Antigen testing. We are also expecting news from Cytiva through Avacta to say the Affirmers are tested and ready for production on their lateral flow devices.
So the times to be able to buy at these levels really is fading quickly.
If you ask I am confident, I am as sure as Alastair said yesterday when he said the hard work is over, the rest of the work here is just a formality.
Holding now close to 500k of shares here. I expect to hold for many years to come!
Cheers RK

Hi AM,
Just to give you my hint from the other day:
Looking at manufacturing opportunities...
I would like to know if a company in York, Abingdon Health have been working with Avacta? If you look they manufacturer Lateral Flow Test devices. For the UK market it would be a strong partnership if they were able to work together. https://www.abingdonhealth.com/contract-services/lateral-flow-assay-development/
Very local opportunity, one would think the two businesses would have some contact?
Cheers RK

This detailed update on the company this afternoon was a superb insight into what I have been underlining for some time. This company has so much to offer through its partnerships. There were multiple hints again in the presentation on values of the potential markets they are entering and in each case they are offering unique selling points and products and technologies that are market-disrupting but which can be applied through either new or existing platforms.
I know someone on the forum here the other day said they are like offering an operating system which can perform on many existing technologies which are key to fast rollouts on some platforms. Other products are clearly going to be unique. But once approved will become the market leader. Just one part of the chemotherapy world - AST, Breast and Ovarian cancer the EU/ US market potential is unfortunately $1.5 billion.
The Affirmer projects with LG Chem just on licensing up to $310 million. Then the project with ADC backed by Astra Zenica for PBD Warheads - loaded affirmer drugs $500 million. Then you have the JV which Avacta hold 45% of the business but the finance is provided by venture capitalists where the market potential is still too large to actually pinpoint as there are NDA's in place so the market information can't be shared. The huge project with Affirmers with Moderna which again will give drug deliveries for mRNA deliery is still progressing.
There are existing 5 other Affirmer evaluations progressing, 17 other projects already delivered for evaluation, and a further 7 development projects initiated!
All of the above are ahead of the multiple partners for Affirmers to detect Covid19 using Antigen tests. None partners are:
Cytiva
Adeptrix - with distribution through 4 Mass Spectrometer suppliers
But still, there are other partners which discussions are underway with (one I hinted at the other evening)!
The upside potential and scale here is like no other company I have ever researched!
The opportunities for success in so many areas are incredible. I do hope if you have not had a chance to watch this you are able to soon.
The one question I would ask is also when are we moving to the FTSE? But, given how busy Alastair Smith is right know with the team. I am not sure they have time to even look at that!
This is certainly a long term hold. Yes, we have some very strong upside coming very soon, but the long term upside would take years of hit and miss with other AIM companies. I think I am going to be very content to hold this for years to come!
If you haven't bought in after that presentation. You should not be even looking at investments and should give up your investment hobbies or careers! Just use an ISA or SIPP or you will be paying a lot of capital gains tax!
Not advice just a very sincere opinion!
Cheers, RK

Thanks Pdub. I have messaged you both. Much appreciated!
Sorry for O/T all contributors!

Hi Pdub,
Can I ask if you or GND, would be able to sign up to Twitter and find me on Twitter (same avatar), please? I would like to be able to direct message you. This would be a very simple solution for us. Thanks my friend!
Cheers, RK

Now is the time to buy today!
That’s all I am saying.

It was a condition of the purchase of Cytiva. http://investors.danaher.com/2020-04-30-Danaher-Completes-Sale-Of-Certain-Businesses-To-Sartorius-AG-To-Satisfy-Regulatory-Requirement-For-Cytiva-Acquisition
Cheers RK

Not if there is an RNS before the webinar

Mostin - here it is in black and white:-
Avacta Group, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that, in only four weeks and well ahead of schedule, it has successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen as part of the collaboration with Cytiva (formerly GE Healthcare Life Sciences) to develop an Affimer-based rapid test for the COVID-19 coronavirus infection.

The process of generating new Affimer reagents to detect the SARS-COV-2 viral antigen was started in mid-March, shortly before the Company announced its collaboration with Cytiva. Multiple highly specific Affimer binders have now been generated that bind to the spike proteins of the SARS-COV-2 virus and do not cross-react with other very closely related viruses, such as SARS and MERS.

These Affimer reagents will be characterised by Avacta with the aim of developing a laboratory test for the SARS-COV-2 virus antigen within the next few weeks. These Affimer binders will also be transferred to Cytiva shortly for implementation in a point-of-care test strip, similar in appearance to a pregnancy test, giving a visual read-out in minutes using a sample such as saliva.

Avacta owns the intellectual property relating to the SARS-COV-2 Affimer reagents and retains all commercial rights. Avacta is in active discussion with other global diagnostic companies to develop Affimer-based COVID-19 antigen tests to increase high-throughput testing capacity on a world-wide scale.
It’s a fact.
Cheers RK

To quote an explanation from a very respectable expert in Pharmaceutricals I know: -
with tests that look for an RNA fragment that might easily be the case but with the AFFIMER it's sort of Binary - either it grabs the virus by the spike - or it doesn't so it never grabs the wrong Virus and gives a false positive and so long as the viral load is above a minimum threshold so there are virus particles in the saliva to grab if they are there - it gets them. Voila.
There you have it!
Cheers RK

Ade, I don’t think you know how Affirmers work. They pick up the exact cell and identify the virus 100% accurately. That is why the BAMS is going to speed up in hospital testing and why the LFD with the partnership with Cytiva will sell in the billions of units!
If that is not exciting enough for you Avacta are going to change the way cancer treatments are administered so they only target the cancer cells using precision technologies. This has the potential to be the biggest step forward in oncology for years once approved.
So maybe you should invest in this growing company whilst you still can! It might multiply the gains made in other recent success stories like NYCT and others.
Only you can decide if a test which everyone can use is going to be valuable to the planet.
Cheers RK

Good afternoon All,

I am delighted given the times we are in to see the team at Bushveld have confirmed the constant focus on delivering not only a solid first quarter in 2020, but continued to support the community which is close to Fortune's heart.
The business has improved on as many metrics it has in its control and taken prudent decisions in using its cash reserve to help fund key projects ready to drive the business forward.
It is great to see the news that the East London Electrolyte plant is going ahead as soon as the builders can get on with the works and the funding is absolutely nailed.
I am also very pleased to see the Vanchem figures which are really strong for our first quarter and with the upgrades coming the potential increase in output is going to be strong. It is also very interesting to see that the operation costs are inline with Vametco.
On Vametco I am pleased to have confirmed the maintence is completed and the rest of the year we will see the operation at capacity.
Given the exchange rate, the low operation cost will be a huge benefit to the business as the year goes on. It is impossible to predict the effect on vanadium prices as long as the global shut down continues, but demand, once we come out, is likely to be bigger than ever. The focus will be on large infrastructure projects and energy storage will be a huge part of new world order. We want clear skies and low emissions to continue!
My holding here represents a very large part of my investment portfolio and my long term position remains focussed on seeing this company become the number 1 in the vanadium world with the largest high grade resource with Mokopane which hopefully will finally open to mine in 2021. In life that is very close!
The new SP angel broker target given the situation is strong and positive. Many companies are on there knees today, but Bushveld Minerals is forging ahead with vanadium strong intent!
SP Angel Broker Note
https://www.uploadlibrary.com/SPAngel_JohnMeyer/Bushveld_Q1_Prodn_2020.pdf
Always a good read: https://www.cnbcafrica.com/mining/2020/02/04/how-this-african-company-plans-to-take-advantage-of-the-worlds-rush-for-battery-metals/

Cheers, RK

This is the real close!

Positive result for all those who managed to buy more this morning, on the dip down to 103. Highest opportunity to sell was around 116.4. But the days maximum and minimums are not the stories here. That is just one day in a huge oppertunity which is opening up in a massive way.
I think Myles has already earlier given the fact that Avacta have two out of four solutions available but they have the big one - the POC Lateral Flow device - the fast low cost one which will be 100% accurate - the critical testing device that every government wants for its people!
So today's close is great news but in 3 months time, I wonder where the close will be £4, £5, the numbers may be higher still!
As the year progresses and this device becomes the one 'the world takes for granted' in terms of a test - 'it gives you access to life'. You can be sure it will be the number one test in the world! That is very good news for investors here!
Cheers, RK

We are through! NT to buy!

Moving on up! ;-)

Good to see you hear AM!
You are right with a very positive outlook. This company is very savvy indeed and the multiple opportunities to succeed and grow there presence in this super needy situation is immense. Some may see the market as being swamped with options and this is always going to be the case when the best minds in the world are set a task with an infinite budget. Let's get a solution! But as Ophidian has already pointed out the Affirmers give super accurate results cause they are looking for one thing and that is the detectable part of this exact virus. Once it has it, it is a clear yes or no. So the test either positive or not and this is the game changer with this identification method and that is why Avacta will be the key partner for multiple partnerships in the Covid19 battle. It is geat yet again to see a British invention which will change the world in the months ahead!
Add to the up and coming targeted cancer treatments and life-changing developments from stem cell researched treatments and you have a company set to transform multiple avenues of healthcare and improve peoples lives.
The best thing is investors reading this board are becoming informed and sharing the story and ultimately have the potential to say there were invested in this incredible company when it mattered. Most people in life miss these opportunities.

To learn everything about the business sign up for the webinar on Wednesday at 17:00 - https://webcasting.brrmedia.co.uk/broadcast/5e985bc231da814c9fc6a477

Cheers, RK

Good morning all,
A new day and a new week! There are multiple new opportunities this week for Avacta which can all have a huge influence on the future for the business. But I am looking forward to the webinar on Wednesday at 5pm for the review and the outline of the roadmap for the future of Avacta. Should be very interesting indeed.
Today I will be very happy if we have a finish with a £1.2? number.
Cheers RK

If we gat an RNS they will certainly spike the SP upwards. Look at the first 15 minutes after the last two significant RNS’s.
I expect another partnership very soon. I hinted earlier who it could be.
Cheers RK

Banjowest it sounds like the market makers are going to need some shares! They are good at games to spread worry amongst PI’s, unless we get an RNS in the morning then we can expect the mother of all spikes! All the best with your buying strategy.
Cheers RK